Filtered By:
Condition: Menopause
Therapy: Hormonal Therapy
This page shows you your search results in order of date.
Order by Relevance | Date
Total 105 results found since Jan 2013.
Transgender health and the impact of aging and menopause
Climacteric. 2023 Apr 3:1-7. doi: 10.1080/13697137.2023.2176217. Online ahead of print.ABSTRACTGender affirming hormone therapy (GAHT) is used by many transgender people to reduce gender incongruence and improve psychological functioning. As GAHT shares many similarities with menopausal hormone therapy, clinicians supporting people through menopause are ideally placed to manage GAHT. This narrative review provides an overview of transgender health and discusses long-term effects of GAHT to consider when managing transgender individuals across the lifespan. Menopause is less relevant for transgender individuals who take GAH...
Source: Climacteric - April 3, 2023 Category: Geriatrics Authors: A S Cheung B J Nolan S Zwickl Source Type: research
The effect of menopausal hormone therapy on the risk of melanoma and keratinocyte skin cancer: A systematic review and meta-analysis of observational studies
The re-analysis of Women's Health Initiative and the publication of data emerging from recent clinical trials data have restored the initial decline in the use of menopausal hormone therapy (MHT), due to adverse events, such as stroke and pulmonary embolism [1,2]. Nowadays, an increasing number of women treat their menopausal symptoms with hormonal therapies, which exhibit a better safety profile. However, the association of MHT with cancer development remains a potent drawback, with breast and endometrial cancer being the most frequently reported neoplasms [3,4].
Source: Maturitas - November 4, 2022 Category: Primary Care Authors: Konstantinos Lallas, Panagiotis Anagnostis, Patroklos Theocharis, Eirini Boureka, Athanasios Kyrgidis, Eleftherios Klonos, Georgios Papazisis, Zoe Apalla, Aimilios Lallas, Efstratios Vakirlis Tags: Review article Source Type: research
Menopausal hormone therapy with conjugated equine estrogen is associated with a higher risk of hemorrhagic stroke than therapy with estradiol: a retrospective population-based cohort study
Estrogen therapy is prescribed for women without a uterus. For women with intact uteri, progestogens should be added to protect against endometrial hyperplasia. Different estrogen profiles may cause different side effects and beneficial clinical outcomes [1]. Different forms of estrogen also have different serum E2 concentrations; a previous study demonstrated that 1 mg E2 was equivalent to 0.4 mg CEE [1]. Progestin includes medroxyprogesterone acetate (MPA) and norethindrone acetate (NE). In Taiwan, the most common MHT for patients with an intact uterus are CEE (0.625 mg) or E2 (2 mg) combined with 5 mg MPA or 1 mg NE [2,3].
Source: Maturitas - August 1, 2022 Category: Primary Care Authors: Wei-Chuan Chang, Jen-Hung Wang, Dah-Ching Ding Tags: Original article Source Type: research
Sex and Gender Considerations in Episodic Migraine
AbstractPurpose of ReviewWe seek to update readers on recent advances in our understanding of sex and gender in episodic migraine with a two part series. In part 1, we examine migraine epidemiology in the context of sex and gender, differences in symptomatology, and the influence of sex hormones on migraine pathophysiology (including CGRP). In part 2, we focus on practical clinical considerations for sex and gender in episodic migraine by addressing menstrual migraine and the controversial topic of hormone-containing therapies. We make note of data applicable to gender minority populations, when available, and summarize kn...
Source: Current Pain and Headache Reports - June 9, 2022 Category: Neurology Source Type: research
Menopausal hormone therapy and risk of cardiovascular events in women with prediabetes or type 2 diabetes: A pooled analysis of 2917 postmenopausal women
CONCLUSIONS: MHT is associated with statistically reduced CVD risk among white but not black women with PreDM or DM. Race is an effect modifier in the association between MHT use and CVD.PMID:35114556 | DOI:10.1016/j.atherosclerosis.2022.01.016
Source: Atherosclerosis - February 3, 2022 Category: Cardiology Authors: Yilin Yoshida Zhipeng Chen Robin L Baudier Marie Krousel-Wood Amanda H Anderson Vivian A Fonseca Franck Mauvais-Jarvis Source Type: research
The impact of micronized progesterone on cardiovascular events - a systematic review
In conclusion, while available data suggest that MP as a component in combined MHT may have a neutral effect on the vascular system, more RCTs investigating the impact of MP alone or in combined MHT on vascular primary endpoints are needed.PMID:35112635 | DOI:10.1080/13697137.2021.2022644
Source: Climacteric - February 3, 2022 Category: Geriatrics Authors: L M Kaemmle A Stadler H Janka M von Wolff P Stute Source Type: research
Hormone therapy in the postmenopausal years: considering benefits and risks in clinical practice
AbstractBACKGROUNDMenopausal symptoms can be very distressing and considerably affect a woman ’s personal and social life. It is becoming more and more evident that leaving bothersome symptoms untreated in midlife may lead to altered quality of life, reduced work productivity and, possibly, overall impaired health. Hormone therapy (HT) for the relief of menopausal symptoms has been the obj ect of much controversy over the past two decades. At the beginning of the century, a shadow was cast on the use of HT owing to the concern for cardiovascular and cerebrovascular risks, and breast cancer, arising following publication ...
Source: Human Reproduction Update - August 25, 2021 Category: OBGYN Source Type: research
The role of medications in successful aging
Climacteric. 2021 May 12:1-8. doi: 10.1080/13697137.2021.1911991. Online ahead of print.ABSTRACTSuccessful aging includes good health and low levels of disability. To that end, primary prevention is far better than managing subsequent organ damage. When medication is needed to prevent or manage disease, the preferred choice should be associated with the greatest benefits and fewest adverse effects. Cardiovascular diseases are the leading cause of morbidity and mortality in postmenopausal women worldwide. Considering disease-adjusted life years, other leading causes are chronic obstructive pulmonary disease, diabetes mellit...
Source: Climacteric - May 12, 2021 Category: Geriatrics Authors: R D Langer Source Type: research
Current Perspective on Menopause Hormone Therapy and Cardiovascular Risk
AbstractPurpose of reviewIn past decades, there has a been a paradigm shift concerning menopause, hormone therapy (HT), and cardiovascular disease (CVD). While initial observational studies suggested hormone replacement to provide a cardioprotective benefit for all menopausal women, subsequent large randomized trials have not confirmed these benefits and furthermore brought to light the risks of HT with regard to CVD, venous thrombosis, and stroke. The goal of this review is to summarize current recommendations regarding HT as it pertains to cardiovascular risk.Recent FindingsMenopause HT remains the most effective treatme...
Source: Current Treatment Options in Cardiovascular Medicine - May 5, 2021 Category: Cardiology Source Type: research
